Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Search Results for:
NCT01767311
Video interviews
View all
5:48
Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk
Nicolas Villain
• 6 Dec 2022
6:01
The development of lecanemab & rationale behind its unique binding profile
Lars Lannfelt
• 17 Mar 2022
1:38
The potential of lecanemab for the treatment of early Alzheimer’s disease
Chad Swanson
• 13 Aug 2021
2:02
Lecanemab for the treatment of early Alzheimer’s disease: the story so far
Chad Swanson
• 13 Aug 2021
Video press briefs
View all
10:19
Clinical trial for BAN2401 in early Alzheimer’s: combining ADCOMS and Bayesian statistics
Lynn Kramer
• 22 Jul 2018
11:32
Outstanding amyloid response to BAN2401: slowing progression in early Alzheimer’s
Lynn Kramer
et al.
• 22 Jul 2018
Features
View all
Potential new therapies for Alzheimer’s disease to look out for in 2022: anti-amyloid-β antibodies
